Journal of the American Academy of Dermatology
Издатель: Elsevier · ISSN 0190-9622 · 90 статей
- Toward context-aware and not context-driven, artificial intelligence in dermoscopic diagnosis. Response to Nouyed et al., “The cost of AI sycophancy in dermoscopic diagnosis”
- The cost of AI sycophancy in dermoscopic diagnosis: Comment on “Framing bias in a large language model: Prompt framing influences ChatGPT's accuracy in melanoma classification. A diagnostic accuracy study”
- Response to Lazarowitz et al, “Contextualizing optical prism use within ergonomic principles in dermatologic surgery”
- Contextualizing optical prism use within ergonomic principles in dermatologic surgery
- From peer review to prompt review
- Are the benefits of JAK inhibitor switching in alopecia areata independent of cumulative treatment exposure?
- Caution in interpreting tralokinumab outcomes in dupilumab nonresponders
- Reply to Yılmaz et al, “Caution in interpreting tralokinumab outcomes in dupilumab nonresponders”
- Switching from deuruxolitinib to baricitinib in alopecia areata: A real-world cohort of 36 patients
- Response to Hermosa-Gelbard et al., “Switching from deuruxolitinib to baricitinib in alopecia areata: A real-world cohort of 36 patients”
- Re: Comparative and complementary diagnostic value of dermatoscopy and clinical close-up photography in skin cancer diagnosis: A study from the MILK10k dataset
- Response to Bisha et al., “Re: Comparative and complementary diagnostic value of dermatoscopy and clinical close-up photography in skin cancer diagnosis: A study from the MILK10k dataset”
- Response to Du et al, “Beyond gastrointestinal symptom burden: Integrating fecal calprotectin into a multimodal safety strategy before initiating bimekizumab in hidradenitis suppurativa”
- Beyond gastrointestinal symptom burden: Integrating fecal calprotectin into a multimodal safety strategy before initiating bimekizumab in hidradenitis suppurativa
- Response to Wang et al, “Cartilage grafts for alar reconstruction in nasolabial interpolation flap surgery may negatively affect breathing function and cosmesis: A retrospective study”
- Accredited compounding pharmacies: A complementary approach to injectable triamcinolone acetonide shortages
- Response to Smith et al, “Accredited compounding pharmacies: A complementary approach to injectable triamcinolone acetonide shortages”
- Response to the letter by Ghanim et al, “Comment on Gao et al’s ‘A multicenter, randomized, double-blinded, placebo-controlled phase III trial to evaluate efficacy and safety of picankibart in moderate-to-severe plaque psoriasis’”
- Comment on Gao et al’s “A multicenter, randomized, double-blinded, placebo-controlled phase III trial to evaluate efficacy and safety of picankibart in moderate-to-severe plaque psoriasis”
- Hispanic ethnicity does not influence the relationship between obesity with atopic dermatitis: Response to Letter regarding Hispanic ethnicity as a covariate
- Hispanic ethnicity as an unconsidered variable in the obesity‑atopic dermatitis relationship
- Response to Guan et al, “Letter to the Editor ‘Rethinking routine cartilage grafting for alar defects’”
- Rethinking routine cartilage grafting for alar defects
- Methodologic considerations and real-world challenges in evaluating the long-term efficacy of 5-fluorouracil for Bowen's disease: A response to Moermans et al
- Response to Zhao, “Methodologic considerations and real-world challenges in evaluating the long-term efficacy of 5-fluorouracil for Bowen disease: A response to Moermans et al”
- Considerations on the relation between Medicaid expansion and overall survival in patients with resected Merkel cell carcinoma
- Response to Fuentes and Joshi, “Considerations on the relation between Medicaid expansion and overall survival in patients with resected Merkel cell carcinoma”
- Response to Jean et al, “Alopecia after glucagon-like peptide-1 agonist therapy: A TriNetX Database active comparator retrospective cohort study”
- Methodological concerns regarding “Alopecia after GLP-1 agonist therapy: A TriNetX database active comparator retrospective cohort study”
- December 2026 iotaderma (#394)